1-3 of 3
Andrew Hodgson
Close
Sort by
Journal Articles

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Niamh Appleby, FRCPath, Fiona M Quinn, PhD, David O'Brien, FAMLs, Smyth Liam, MRCPI, Johanna Kelly, BSc, Imelda Parker, Kathleen Scott, PhD, Mary R Cahill, MB, FRCPath, Gerard Crotty, Helen Enright, MD FRCPI, FRCPath, Brian Hennessy, MD MRCPI, FRCPath, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Maeve Leahy, FRCPath, Hilary M O'Leary, FRCPath, Michael E O'Dwyer, MD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD
Journal: Blood
Blood (2016) 128 (22): 3237.
https://doi.org/10.1182/blood.V128.22.3237.3237
Published: 2016
Journal Articles

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Janusz Krawczyk, MD, MRCP, Sahar Khan, Bushra Ahsan, Larissa Higgins, Enda McGowan, Safa Eltom, Khalid Awad Saeed, Carmelita Gibbons, Karen Maloney, Teresa Meenaghan, Geraldine Walpole, Catriona Collins, Robert Snedker, Moutaz Abdelrahmen, Amjad Hayat, MBBS, PhD, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Margaret Murray, MD, MRCPath, Michael E O'Dwyer, MD, FRCPI, FRCPath
Journal: Blood
Blood (2013) 122 (21): 5396.
https://doi.org/10.1182/blood.V122.21.5396.5396
Published: 2013
Journal Articles

An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans–associated meningococcemia

Clinical Trials & Observations
Barry White, Wendy Livingstone, Ciaran Murphy, Andrew Hodgson, Marie Rafferty, Owen P. Smith
Journal: Blood
Blood (2000) 96 (12): 3719–3724.
https://doi.org/10.1182/blood.V96.12.3719
Published: 2000